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chronic inflammation is associated with
cardiac-specific mortality in stable hemodialysis
patients
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Background: Elevated cardiac troponin I (TnI) levels are associated with all-cause mortality in stable hemodialysis
patients. Their relationship to cardiac-specific death has been inconsistent, and the reason for their elevation is not
well understood. We hypothesized that elevated TnI levels in chronic stable hemodialysis patients more specifically
track with cardiac mortality, and this mechanism is independent of other contributors of cardiac mortality, such as
inflammation.
Methods: We conducted a single-centre, cohort study of prevalent hemodialysis patients at a tertiary care hospital.
Plasma TnI levels were measured with routine monthly blood tests in clinically stable patients for two consecutive
months. Plasma TnI was measured by immunoassay and a value above the laboratory reference range (0.06 μg/L)
was considered elevated. The primary outcome of death was adjudicated separately for this study, and classified as
cardiac, non-cardiac, or unknown. Cox proportional hazard models were used to examine the association of TnI
with the all-cause and cardiac-specific mortality, adjusting for potential confounders, including C-reactive protein
(CRP) as a marker of inflammation.
Results: Of 133 patients followed for a median of 1.7 years, there were 38 deaths (58% non-cardiac, 39% cardiac,
3% unknown). Elevated TnI was associated with adjusted HR for all-cause mortality of 2.57 (95% CI 1.30-5.09) and an
adjusted HR for cardiac death of 3.14 (95% CI 1.07-9.2), after accounting for age, time on dialysis, diabetes status,
prior coronary artery disease history, and C-reactive protein. Although CRP was also independently associated with
all-cause mortality, it did not add prognostic information to TnI for cardiac-specific death.
Conclusion: Elevated TnI levels are independently associated with cardiac and all-cause mortality in asymptomatic
hemodialysis patients. The mechanism for this risk is likely independent of inflammation, but may reflect chronic
subclinical myocardial injury or unmask those with subclinical atherosclerotic heart disease. Whether those with
elevated TnI levels may benefit from additional investigations or more aggressive therapies to treat cardiovascular
disease remains to be determined.* Correspondence: ahsan.alam@mcgill.ca
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Cardiovascular disease (CVD) has been well recognized
as the leading cause of mortality for patients on chronic
hemodialysis, accounting for 45% of deaths [1-3]. Despite
the burden of traditional CVD risk factors in this popula-
tion, conventional (i.e. blood pressure or lipid lowering)
and non-conventional treatment strategies (i.e. anemia
and bone mineral disease management) have not been
demonstrated to improve patient survival in this popula-
tion [4]. Understanding the pathophysiologic mechanisms
leading to this increased cardiac mortality need to be
re-explored.
Subclinical myocardial ischemia and injury may be
under-recognized in otherwise stable patients receiv-
ing renal replacement therapy. In hemodialysis, car-
diac troponin T and troponin I (TnI) levels have been
extensively studied. These studies are often heteroge-
neous, particularly with respect to TnI, and do not
account for non-traditional cardiac risk factors, such
as inflammation [5].
The aim of our study was to examine the association
of elevated TnI levels in stable patients receiving main-
tenance hemodialysis therapy with cardiac-specific mor-
tality, and discern if any increased risk was independent
of inflammation status. Using a cohort study design, we
measured plasma TnI levels with routine pre-dialysis
monthly blood tests, including CRP, and tracked all pa-
tient outcomes, specifically adjudicating the cause of all
deaths as cardiac or non-cardiac.
Methods
Study design
This was an observational, single-centre cohort study of
prevalent hemodialysis patients at a tertiary care hos-
pital. All clinically stable (i.e. non-hospitalized) chronic
hemodialysis patients available both in July and August
2009 were followed prospectively until July 2012. This
study was approved by the Research Ethics Board of the
McGill University Health Centre. All blood tests were
measured routinely in the hemodialysis unit at the time
of the study and processed through the hospital’s central
laboratory. Thus the institutional REB waived individual
patient consent for use of existing clinical data. The
study was conducted according to the Helsinki declar-
ation for medical research in humans.
Study participants
The inclusion criteria were all adult patients (age 18 years
or older) receiving chronic hemodialysis irrespective of
dialysis prescription, frequency, or vascular access. All
patients in our dialysis unit received dialysis using a high
flux membrane. Patients that were hospitalized or did
not have a routine monthly blood test were excluded
(N = 10).Data collection
Detailed data on demographic characteristics, medical
history, medications, and routine laboratory tests from
dialysis monthly blood work (complete blood count,
serum electrolytes, iron profile, ferritin, albumin, cal-
cium, phosphate, intact parathyroid hormone, and urea
reduction ratio) were collected at baseline. If required,
any missing data was captured from the hospital elec-
tronic medical record system or medical chart review.
At the time of the study, C-reactive protein (CRP) was
included as part of the routine dialysis monthly blood
work on a bimonthly basis.
Plasma TnI levels were drawn pre-dialysis in clinically
stable patients for two consecutive months. Patients with
a hospital visit in the prior two weeks were not enrolled
in this cohort. We reviewed all presentations to hospital
in the prior two months. Sixteen patients had a troponin
value measured in the prior two months, with only 5 pa-
tients showing any elevation, but all returned to within
‘normal-range’ by study initiation. In retrospect, one of
the 5 individuals enrolled was found to have been admit-
ted to the coronary care unit within the prior two months.
This individual’s TnI normalized by study inclusion (TnI
level <0.06) and he was included in the study analysis.
Troponin I was measured by immunoassay (Beckman
Coulter, Inc.) by the central laboratory in the hospital. Sam-
ples were assayed immediately, and were not frozen. The
mean value from both months was used for the analysis. A
value above the laboratory reference range (0.06 μg/L) was
considered elevated.
Outcome measures
The primary outcome for this study was cardiac-specific
mortality. A secondary outcome was all-cause mortality.
The date of all deaths is captured prospectively by the
dialysis unit. The cause of death was ascertained by both
dialysis and medical chart review by study investigators
(AP, AA and AS) who were blinded to the TnI data. Ad-
judication as to the cause of death was by consensus and
classified as ‘cardiac’, ‘non-cardiac’, or ‘unknown’.
Criteria for determining cardiac death required recog-
nition of an acute coronary syndrome, congestive heart
failure, or a fatal arrhythmia. For all in-hospital deaths, a
review of all laboratory tests, including cardiac enzymes,
as well as available electrocardiograms and cardiac im-
aging studies, such as coronary angiography, were used to
establish a cause of death. For deaths outside the hospital
we reviewed the last hemodialysis treatment run sheets
and nursing or physician notes, or if available, ambulance
and emergency room notes to identify any support for a
cardiovascular death. Rarely, autopsy data was available to
provide a definitive cause of death. The presence of an al-
ternative cause of death or any withdrawal from dialysis
was classified as non-cardiac.
Table 1 Baseline patient study characteristics stratified
by troponin I level elevation
TnI < 0.06 TnI ≥ 0.06 p
N = 97 N = 36
Age, years 68.4 ± 14.0 65.4 ± 17.1 0.30
Male (%) 54 (56) 26 (72) 0.08
CAD history (%) 31 (32) 10 (28) 0.64
PVD history (%) 14 [16] 5 [18] 0.81
Diabetes mellitus (%) 36 (37) 21 (58) 0.03
Hypertension (%) 75 (86) 27 (93) 0.33
Dyslipidemia (%) 43 (49) 15 (51) 0.83
Smoking status (%) 0.15
Never 60 (71) 15 (52)
Current 13 [15] 7 (24)
Ex-Smoker 11 [13] 7 (24)
Dialysis vintage, median years 2.0 (0.9-4.0) 2.9 (1.2-4.2) 0.57
Hemoglobin, g/L 111 ± 16 112 ± 19 0.81
Ferritin, μg/L 607 ± 425 505 ± 344 0.12
Albumin, g/L 32.1 ± 4.5 30.4 ± 5.3 0.08
Calcium total, mmol/L 2.19 ± 0.16 2.18 ± 0.09 0.81
Phosphorus, mmol/L 1.57 ± 0.48 1.54 ± 0.58 0.80
Urea reduction ratio, % 74.2 ± 8.0 70.2 ± 10.1 0.03
CRP, median mg/L 5.0 (1.7-13.4) 8.9 (4.1-21.3) 0.03
CAD, Coronary artery disease; PVD, Peripheral vascular disease; CRP,
C-reactive protein.
Data are presented as frequency (proportion), means ± SD, or median
(interquartile range).
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Baseline demographics and clinical characteristics are
presented as means or medians and proportions, as ap-
propriate. Natural log transformations of both TnI and
CRP were performed due to their skewed distribution.
Cox proportional hazard models were used for time-to-
event analyses for both cardiac-specific and all-cause
mortality outcomes. Proportional hazards assumptions
were tested using log-negative-log survival plots. All
models assessing the association of troponin I with mor-
tality were adjusted for clinically relevant confounders and
selected covariates that were significant from univariate
analyses at a p-value less than 0.10. Censoring occurred
for patients that transferred to another hemodialysis unit
or switched dialysis modality (N = 6), had a kidney trans-
plant (N = 5), or reached the end of the observation period
(July 1, 2012).
Several sensitivity analyses were performed. The ana-
lyses were repeated using tertiles of TnI, a TnI cutoff
of 0.10 μg/L, and natural log-transformed TnI as a
continuous measure (Additional file 1: Table S1). Serum
albumin was also examined as a marker of inflammation-
malnutrition. All models were re-analyzed with serum
albumin added to the adjusted model with CRP, and adjust-
ing for serum albumin without CRP (Additional file 2:
Table S2).
All analyses were done using SAS software version 9.2
(SAS Institute Inc. Cary, North Carolina).
Results
In this stable hemodialysis population there were 36
patients (27%) with a TnI level greater than 0.06 μg/L.
The mean TnI level was 0.06 ± 0.11, with a median value
of 0.03 (IQR 0.02-0.06) mcg/L. Table 1 describes the
demographic and baseline variables in those with and
without an elevated TnI level. The prevalence of diabetes
mellitus was significantly higher in those with a higher
TnI level (58 vs. 37%, p = 0.03). The mean dialysis dose
measured by urea reduction ratio was adequate in both
groups, but was lower in those with an elevated TnI
(70% vs. 74%, p = 0.03). C-reactive protein was signifi-
cantly higher in those with a TnI level above the normal
range (median 8.9 vs. 5.0, p = 0.03). Patient age, gender,
a history of coronary or peripheral vascular disease,
hypertension, dyslipidemia, smoking status, and time
on dialysis did not associate with a higher TnI level.
Although urea reduction ratio was lower in those
with higher TnI, it was not associated with all-cause
or cardiac-specific mortality in univariate analyses,
and thus was not included as a confounder in multi-
variable models.
The median observation period was 1.7 years (interquar-
tile range 1.2 to 2.7 years). There were 38 deaths amongst
133 study participants. Of the 38 deaths, 22 patients werehospitalized at the time of death; the causes of death for 2
patients were confirmed by autopsy. Fifteen deaths were
adjudicated as cardiac (N = 7) or sudden cardiac death
(N = 8), and 22 were non-cardiac in nature. A cause could
not be determined in one individual, and thus classified as
non-cardiac for the purpose of our analysis.
A TnI level greater than 0.06 μg/L was associated with
an increased hazard ratio (HR) of 2.57 (95% CI 1.30-5.09)
for all-cause mortality even after adjusting for potential
confounders, including CRP (Table 2). The association of
TnI with cardiac-specific mortality was even stronger with
an adjusted HR of 3.14 (95% CI 1.07-9.20). C-reactive pro-
tein was also independently associated with all-cause
mortality, adjusted HR 1.37 (95% CI 1.07-1.75) per natural
log increase. However, after adjusting for TnI level, CRP
did not associate with cardiac-specific mortality. Diabetes
mellitus was also independently associated with cardiac-
specific mortality and trended towards a significant associ-
ation with all-cause mortality. Variables such as gender,
prevalent hypertension, dyslipidemia, or smoking status
were not associated with mortality in univariate models,
thus they were not considered further in our multivariable
analysis.
Table 2 Cox proportional hazard ratios for the association of troponin I level with all-cause and cardiac-specific
mortality
All-cause mortality Cardiac-specific mortality
Model Unadjusted Adjusted Unadjusted Adjusted
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
TnI ≥0.06 2.83 (1.49-5.37)* 2.57 (1.30-5.09)* 4.04 (1.46-11.2)* 3.14 (1.07-9.20)*
Age (per year) 1.01 (0.99-1.04) 1.01 (0.99-1.04) 1.00 (0.97-1.04) 1.00 (0.96-1.04)
Months on dialysis 0.99 (0.91-1.08) 1.01 (0.93-1.10) 1.01 (0.90-1.14) 1.07 (0.95-1.20)
CAD history 1.70 (0.90-3.23)† 1.60 (0.84-3.07) 1.85 (0.67-5.09) 1.71 (0.61-4.82)
Diabetes mellitus 2.14 (1.12-4.08)* 1.77 (0.89-3.51)† 4.40 (1.40-13.8)* 4.33 (1.22-15.3)*
CRP (per natural log) 1.40 (1.11-1.70)* 1.37 (1.07-1.75)* 1.27 (0.88-1.82) 1.20 (0.82-1.76)
TnI, Troponin I; CAD, Coronary artery disease; CRP, CRP.
Adjusted model includes all covariates listed in the table.
*p ≤ 0.05; †p ≤ 0.10.
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robustness of the relationship between TnI and patient
outcomes. Examining TnI as a continuous (natural log-
transformed) variable showed similar results (Figure 1),
as did the cutoff of 0.10 μg/L (Additional file 1: Table S1).
Tertiles of TnI showed a dose–response with both all-
cause and cardiac-specific mortality, but statistical signifi-
cance was not met, likely due to a loss of power from our
limited sample size. Serum albumin (per 1 g/L) was also
inversely associated with all-cause mortality, HR 0.90
(95% CI 0.85-0.95), but not cardiac-specific mortality,
HR 0.94 (95% CI 0.84-1.04). When serum albumin was
added to a fully adjusted model for all-cause mortality, it
remained significant, but did not confound the association
of TnI with all-cause mortality. The significance of CRP
with all-cause mortality was lost when serum albumin was
added to the model (Additional file 2: Table S2).
Discussion
In this study, we report a strong association between ele-
vated TnI level and all-cause and cardiac-specific mor-
tality in non-hospitalized and clinically stable patients
receiving maintenance hemodialysis. This relationship
was independent of other potential confounders, includ-
ing inflammation measured by either CRP or serum al-
bumin. It is notable that although CRP did associate
with all-cause mortality it did not show an independent
association with cardiac-specific mortality after adjusting
for TnI.
Cardiac troponins are a mainstay in detecting acute
cardiac injury in those with and without kidney disease.
In otherwise stable hemodialysis patients elevated tropo-
nin levels have also been shown to predict adverse out-
comes, even in the absence of evident cardiac ischemia.
The prevalence, threshold and significance of TnI eleva-
tion remain uncertain.
There have been numerous studies that have attempted
to examine this issue, even prompting a meta-analysis oncardiac troponins in patients with end-stage renal disease.
[5] This analysis highlighted that the majority of studies
focused on troponin T, which is indeed associated with
total and cardiac mortality. Troponin T is elevated in pa-
tients with impaired renal clearance and on hemodialysis,
requiring the normal cutoff to be different than the gen-
eral population. Fewer studies have examined TnI. Many
of these TnI studies are limited by small sample size, low
event rates, or short observation period [6-14]. Some
applied a much higher TnI cutoff (0.10-2.8 ng/mL) often
due to the use of older assays [15,16]. The meta-analysis
highlighted the heterogeneity between studies, and par-
ticularly the estimates of cardiac-specific death risk being
very highly variable. None of these studies earlier took into
account CRP or inflammation status.
Boulier et al. specifically examined the role of TnI en-
hancing the prognostic value of CRP [17]. In this study
of 191 French hemodialysis patients, TnI was similarly
associated with all-cause as well as cardiovascular deaths,
although the method of adjudicating cause of death was
not specified. Applying a TnI cutoff of 0.03 μg/L, they
found an association with death, with the greatest risk in
those also having a CRP level above 10 mg/L. Our analysis
extends their findings, also demonstrating that the risk
associated with TnI is linear across its range, but most im-
portantly showing that this risk is entirely independent of
CRP. This would suggest that attention on inflammation,
as measured by CRP, in trying to explain cardiovascular
risk in patients on hemodialysis may not warrant the most
focus.
As expected, diabetes mellitus status was also strongly
and independently associated with cardiac-specific mortal-
ity, and more so than with all-cause mortality. Although
inflammation may be highly prevalent in those with dia-
betes, our analysis suggests that these parameters are inde-
pendent in their association with mortality. Interestingly,
patient age did not associate with mortality in our cohort.
Patients who died within the observation period were
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Figure 1 The association of log-transformed troponin I and C-reactive protein with either all-cause or cardiac-specific mortality.
Estimated adjusted hazard ratio (solid line) with 95% confidence intervals (dashed lines) for the association of: A) natural log-transformed
troponin I (LnTnI) with all-cause mortality; B) natural log-transformed C-reactive protein (LnCRP) with all-cause mortality; C) LnTnI with cardiac-specific
mortality; D) LnCRP with cardiac-specific mortality. The median level of TnI or CRP was used as a reference point for the calculation of all hazard ratios.
Non-linear relationships were first examined using restricted cubic splines (knots = 3, p < 0.001 for the test of linear relation). The models are adjusted
for age, time on dialysis, coronary artery disease history, diabetes mellitus status, and either LnTnI or LnCRP, as appropriate.
Alam et al. BMC Nephrology 2013, 14:247 Page 5 of 7
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0.17) than those who remained alive, but this did not
reach statistical significance in survival analysis models.
The lack of association may in part be related to our
exclusion of hospitalized/unstable patients, which we sus-
pect excluded older patients. Also, the age of our dialysis
cohort ranged from 26–93 years of age. These extremes of
age may represent a lower risk population with respect to
cardiac disease, due to selection and survival bias. Simi-
larly, a history of coronary artery disease (CAD) did notpredict cardiac mortality. We characterized CAD from
chart review, but it is unclear whether CAD documenta-
tion by physicians was complete and comprehensive.
Furthermore, severity and treatment of CAD was not
captured, and this may be a greater and more relevant
influence on outcomes.
The causes of troponin release in the absence of myo-
cardial necrosis are numerous (e.g. congestive heart fail-
ure, pericarditis, tachyarrhythmia, pulmonary embolism,
sepsis, etc.), and likely results from increased myocyte
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elevated over at least two months in our patients, we
would expect these traditional causes to become evident or
to be associated with clinical symptoms. Instead, we suggest
that repeated and subclinical ischemia-reperfusion injury
from the hemodynamic effects of intermittent hemodialysis,
particularly in those with a vulnerable myocardium or oc-
cult atherosclerotic disease, to be a more rational hypoth-
esis. Dialysis-specific factors may be related to intradialytic
hyper- or hypotension, aggressive ultrafiltration, electrolyte
shifts, or even bioincompatibility; however, our study was
not designed to address this question. The hypothesis of
“uremic cardiopathy” is also not clearly supported by our
data as the dialysis adequacy would be considered adequate
for both TnI groups. The issue of dialysis-induced myocar-
dial stunning has also been linked to elevated troponin T
levels, but its association with long-term CVD or mortality
outcomes remains to be evaluated [18].
There are several strengths of this study. We charac-
terized TnI levels in a stable hemodialysis population
with close longitudinal follow up. Troponin I levels were
measured on two consecutive monthly visits to establish
a stable baseline level. C-reactive protein was also mea-
sured concurrently as a marker of inflammation, and our
analyses were repeated with serum albumin as well. The
cause of death was classified as cardiac or non-cardiac on
the basis of individual patient charts reviews, with the
adjudicators blinded to the TnI level.
There are limitations to the study as presented. This
cohort is drawn from a single-centre, and may not be
generalizable to all dialysis populations. Although our
results are robust, both in primary and secondary ana-
lyses, we did have limited power to explore subgroups
or additional potential confounders. It is unclear whether
an elevated TnI is determined by patient-specific factors,
such as comorbidities, or whether the hemodialysis treat-
ment or complications related to treatment (e.g. intradia-
lytic hypotension) is the primary contributor to cardiac
risk. We did not capture hemodynamic factors during
hemodialysis sessions, or repeat TnI levels before and after
dialysis. Although we did repeat TnI levels over two
months, serial measurements over longer time were not
captured, and may allow for more accurate detection of
myocardial injury. In our institution CK-MB is not rou-
tinely measured for the diagnosis of an acute coronary
syndrome, and we did not perform other diagnostic or
invasive cardiac testing. Our study population was
selected if they had no presentation to our hospital in
the prior two weeks; however, we could not ascertain
if they presented to another institution or had a myo-
cardial event that was not investigated in the preceding
two months. Also, we did not capture non-fatal outcomes,
as we felt this would be difficult to adjudicate accurately
with respect to cardiac and non-cardiac in nature.Conclusions
Given the magnitude and burden of CVD in patients
with ESRD, it is essential to identify reliable measures of
increased risk. Elevated TnI levels provide independent
prediction of cardiac risk. More important, elucidating
the underlying pathophysiologic processes that lead to
TnI elevation is critical. Our observational study cannot
directly justify a change in clinical practice; however, this
study adds evidence to support a more comprehensive
approach to cardiac risk stratification in dialysis patients,
which may include such tests as exercise or pharmacologic
stress testing. We postulate that ischemia-reperfusion
injury should also be a focus of further investigation in
these otherwise stable chronic hemodialysis patients. The
implication of these results would allow for interventional
studies to address potentially modifiable factors, such as
dialysis prescription or modality changes, indications for
targeted risk stratification, such as functional cardiac
testing, or more aggressive medical management in this
vulnerable population.
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